These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. CXCL10 and CXCL13 chemokines in patients with relapsing remitting and primary progressive multiple sclerosis. Iwanowski P; Losy J; Kramer L; Wójcicka M; Kaufman E J Neurol Sci; 2017 Sep; 380():22-26. PubMed ID: 28870573 [TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal Fluid Biomarkers in Relation to MRZ Reaction Status in Primary Progressive Multiple Sclerosis. Robinson T; Abdelhak A; Bose T; Meinl E; Otto M; Zettl UK; Dersch R; Tumani H; Rauer S; Huss A Cells; 2020 Nov; 9(12):. PubMed ID: 33255854 [TBL] [Abstract][Full Text] [Related]
5. CSF Levels of CXCL12 and Osteopontin as Early Markers of Primary Progressive Multiple Sclerosis. Marastoni D; Magliozzi R; Bolzan A; Pisani AI; Rossi S; Crescenzo F; Montemezzi S; Pizzini FB; Calabrese M Neurol Neuroimmunol Neuroinflamm; 2021 Nov; 8(6):. PubMed ID: 34588298 [TBL] [Abstract][Full Text] [Related]
6. Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a biomarker panel. Stilund M; Gjelstrup MC; Petersen T; Møller HJ; Rasmussen PV; Christensen T PLoS One; 2015; 10(4):e0119681. PubMed ID: 25860354 [TBL] [Abstract][Full Text] [Related]
7. CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis. Romme Christensen J; Börnsen L; Khademi M; Olsson T; Jensen PE; Sørensen PS; Sellebjerg F Mult Scler; 2013 Jun; 19(7):877-84. PubMed ID: 23178691 [TBL] [Abstract][Full Text] [Related]
8. Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity. Kuhle J; Barro C; Disanto G; Mathias A; Soneson C; Bonnier G; Yaldizli Ö; Regeniter A; Derfuss T; Canales M; Schluep M; Du Pasquier R; Krueger G; Granziera C Mult Scler; 2016 Oct; 22(12):1550-1559. PubMed ID: 26754800 [TBL] [Abstract][Full Text] [Related]
9. Tumor necrosis factor-alfa and interleukin-4 in cerbrospinal fluid and plasma in different clinical forms of multiple sclerosis. Obradović D; Kataranovski M; Dincić E; Obradović S; Colić M Vojnosanit Pregl; 2012 Feb; 69(2):151-6. PubMed ID: 22500369 [TBL] [Abstract][Full Text] [Related]
10. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort. Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051 [TBL] [Abstract][Full Text] [Related]
11. Voxel-based assessment of differences in damage and distribution of white matter lesions between patients with primary progressive and relapsing-remitting multiple sclerosis. Di Perri C; Battaglini M; Stromillo ML; Bartolozzi ML; Guidi L; Federico A; De Stefano N Arch Neurol; 2008 Feb; 65(2):236-43. PubMed ID: 18268194 [TBL] [Abstract][Full Text] [Related]
12. Cytokine Profiling in Cerebrospinal Fluid of Patients with Newly Diagnosed Relapsing-Remitting Multiple Sclerosis (RRMS): Associations between Inflammatory Biomarkers and Disease Activity. Gębka-Kępińska B; Adamczyk B; Gębka D; Czuba Z; Szczygieł J; Adamczyk-Sowa M Int J Mol Sci; 2024 Jul; 25(13):. PubMed ID: 39000506 [TBL] [Abstract][Full Text] [Related]
13. Hemispheric asymmetry measured by texture analysis and diffusion tensor imaging in two multiple sclerosis subtypes. Savio S; Hakulinen U; Ryymin P; Hagman S; Dastidar P; Soimakallio S; Elovaara I; Eskola H Acta Radiol; 2015 Jul; 56(7):844-51. PubMed ID: 25024438 [TBL] [Abstract][Full Text] [Related]
14. Approach to discriminate subgroups in multiple sclerosis with cerebrospinal fluid (CSF) basic inflammation indices and TNF-alpha, IL-1beta, IL-6, IL-8. Kleine TO; Zwerenz P; Graser C; Zöfel P Brain Res Bull; 2003 Aug; 61(3):327-46. PubMed ID: 12909303 [TBL] [Abstract][Full Text] [Related]
15. BAFF Index and CXCL13 levels in the cerebrospinal fluid associate respectively with intrathecal IgG synthesis and cortical atrophy in multiple sclerosis at clinical onset. Puthenparampil M; Federle L; Miante S; Zito A; Toffanin E; Ruggero S; Ermani M; Pravato S; Poggiali D; Perini P; Rinaldi F; Gallo P J Neuroinflammation; 2017 Jan; 14(1):11. PubMed ID: 28095856 [TBL] [Abstract][Full Text] [Related]
16. Dimethyl fumarate treatment of primary progressive multiple sclerosis: results of an open-label extension study. Højsgaard Chow H; Talbot J; Lundell H; Marstrand L; Gøbel Madsen C; Bach Søndergaard H; Bredahl Hansen M; Solberg Sørensen P; Siebner HR; Sellebjerg F Mult Scler Relat Disord; 2023 Feb; 70():104458. PubMed ID: 36586351 [TBL] [Abstract][Full Text] [Related]
17. Cell surface adhesion molecules and cytokine profiles in primary progressive multiple sclerosis. Ukkonen M; Wu K; Reipert B; Dastidar P; Elovaara I Mult Scler; 2007 Jul; 13(6):701-7. PubMed ID: 17613596 [TBL] [Abstract][Full Text] [Related]
19. The alterations of cerebrospinal fluid TNF-alpha and TGF-beta2 levels in early relapsing-remitting multiple sclerosis. Grzegorski T; Iwanowski P; Kozubski W; Losy J Immunol Res; 2022 Oct; 70(5):708-713. PubMed ID: 35729473 [TBL] [Abstract][Full Text] [Related]
20. A comparison of serum inflammatory parameters in progressive forms of multiple sclerosis. Nowak-Kiczmer M; Niedziela N; Czuba ZP; Sowa P; Wierzbicki K; Lubczyński M; Adamczyk-Sowa M Mult Scler Relat Disord; 2023 Nov; 79():105004. PubMed ID: 37738756 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]